- Bloomberg•28 days ago
H. Lundbeck A/S is looking at ways to develop combination therapies for Alzheimer’s disease as the Danish brain-disorder specialist presses forward despite recent failures in late-stage patient trials....
- Thomson Reuters StreetEvents•2 months ago
Q4 2016 H Lundbeck A/S Earnings Call
- Reuters•2 months ago
Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer's and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix. The two companies said on Thursday that Lundbeck had made an undisclosed payment to Ossianix, which has labs in Britain, following experiments in mice showing the effective transfer of potential drugs across the blood-brain barrier. Getting modern large-molecule medicines across the barrier that protects the brain is a major challenge for drug developers.
LUN.CO : Summary for H. Lundbeck A/S - Yahoo Finance
H. Lundbeck A/S (LUN.CO)
Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
|Day's Range||315.50 - 318.30|
|52 Week Range||209.40 - 319.20|
|PE Ratio (TTM)||51.60|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|